Flow Cytometry

Flow cytometry is a powerful tool for rapid analysis of biological and physical properties of cells suspended within a high-velocity fluid stream and passing through a laser beam in a single file.

In cancer diagnostics, flow cytometry is used for quantification, biomarker detection, measuring total and/or newly synthesized DNA, and evaluating gene expression.

Flow cytometry in hematopathology is useful for

  • Distinguishing between neoplastic and benign conditions
  • Diagnosing and characterizing leukemias and lymphomas, as well as other disorders, such as plasma cell myeloma and myelodysplastic syndromes
  • Detecting minimal residual disease

Flow Cytometry at NeoGenomics

NeoGenomics utilizes flow cytometers capable of detecting 10+ simultaneous fluorescent signals to offer:

  • increased accuracy in population identification and characterization
  • detailed information from small specimens
  • consistent detection of abnormalities at low levels

Neo’s proprietary antibody preparation method reduces cell drift and increases consistency in serial testing of patient samples.

Tech-Only Option
Available with cytospin images and access to hands-on regating to help increase clients’ confidence in interpretation of test data. Flow User’s Guide is available here.

Flow Cytometry for Hematologic Malignancies


Comprehensive panels are useful for the diagnosis of leukemia, lymphoma, and plasma cell neoplasms.

They can also be used for post-treatment follow-up or evaluation of myeloid maturation.

  • Standard Leukemia/Lymphoma Panel – 24 markers
  • Extended Leukemia/Lymphoma Panel – 31 markers

Add-on panels are available to further aid in the diagnosis and classification of select disease states, supplementing analyses already in progress. Available panels include AML, ALL, CLL, hairy cell, mast cell, plasma cell, PNH, and more.


After diagnosis, follow-up panels are available for monitoring disease or diagnosis of relapse.

Full list of panels includes AML, B-ALL, T-ALL, hairy cell leukemia (HCL), B-Cell and T-Cell lymphoma, and plasma cell.

MRD Testing

Minimal residual disease (MRD) testing by flow cytometry is recommended when assessing response to therapy.

Limit of detection for all available flow panels is 0.01%.

  • B-ALL MRD Panel
  • CLL MRD Panel
  • Myeloma MRD Panel

Note: Tech-only option is not available with MRD panels.

MRD Testing
Client Services

NeoGenomics prides itself on our unparalleled customer support team. If you have questions regarding test information, specimen requirements, turnaround times, test add-on, and patient results, please feel free to reach out to a Client Services Advocate at client.services@neogenomics.com.

Flow Cytometry Testing

View our full menu of available Flow Cytometry tests with printable descriptions and specimen requirements.



Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients